Re: ACADIA Pharmaceuticals Presents New Data
These PD patients did not necessarily have dementia, but the affect seems to be present in all trials regardless.
It’s present in all of our trials. In the discontinued ADA Phase 2 trial which was larger than this trial, placebo beat pima in both doses and in both the primary and secondary end points. The pima results were good, but the placebo results were better in each case. We saw the same thing in week 12 of the Phase 2 ADP trial. Pima was good but so was placebo.